There are limited data on human papillomavirus (HPV) type-specific cervical cancer risk among human immunodeficiency virus (HIV)-positive women. Previous studies have suggested that HPV 16 would be relatively less important as a causative agent among HIV-positive compared with HIV-negative women. This study investigates HPV type-specific cervical cancer risk in a population in which HIV is endemic. At the Central Hospital, Maputo, Mozambique, 221 cervical cancer cases and 203 hospital-based controls were consecutively enrolled. HPV typing from cervical samples, HIV testing and recording of socio-demographic factors were performed. Logistic regression modelling was used to assess HPV type-specific risk and effect modification between HIV and HPV infection. Infection with HPV 16, 18 and 'high-risk non-HPV 16/18 types' (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) was associated with cervical cancer in both crude and adjusted analyses. HPV 16 and 18 were the most common types detected in cancer biopsies among both HIV-negative and HIV-positive women. There was no significant evidence of effect modification between any HPV type and HIV infection, and there were no significant differences in the HPV type-specific prevalence when cervical cancers among HIV-positive and HIV-negative women were compared. Within the limitations of the study, the relative importance of different HPV types in cervical carcinogenesis appears not to be modified greatly by HIV infection, suggesting that HPV vaccines might not need to be type-specifically modified to be suitable for populations where HIV is endemic.
INTRODUCTION
Cervical cancer is an acquired immune deficiency syndrome (AIDS)-defining diagnosis (CDC, 1992) and is a major cause of morbidity and mortality in the developing world (Parkin et al., 2005) . Human papillomavirus (HPV) infection is the major risk factor for development of cervical cancer (Walboomers et al., 1999; Wallin et al., 1999) . Current data indicate that at least 12 different HPV types are carcinogenic, with HPV 16 being uniquely important as a cause of cervical cancer worldwide (Schiffman et al., 2009; Smith et al., 2007) . However, there are limited data in which HPV types are associated with cervical cancer among women with concomitant human immunodeficiency virus (HIV) infection. Previous studies have reported that the effect of immune status among HIV-positive women is relatively less important for HPV 16 prevalence compared with other HPV types, and that HPV16 is less prevalent in high grade cervical cancer precursors among HIV-positive women, thus leading to predictions that HPV 16 would be a relatively less common cause of cervical cancer among HIV-positive women than among HIV-negative women (Clifford et al., 2006; Strickler et al., 2003) . If indeed HIV infection acts as an effect modifier on HPV 16 infection, it could have a substantial impact on cancer-preventive measures utilizing HPV vaccines targeting HPV 16 and 18 in populations with a high prevalence of HIV. In this paper, we present data from a hospital-based case-control study at the Central Hospital in Maputo, Mozambique, a country with an estimated IP: 54.70.40.11
On: Fri, 28 Dec 2018 00: 06:14 adult HIV prevalence of 12 % in 2004 12 % in (UNAIDS, 2011 , where we investigate whether HIV infection modifies HPV type-specific cervical cancer risk.
RESULTS
Socio-demographic characteristics and HIV results are presented in Table 1 . In univariate analysis, control women were younger than cancer cases and were more likely to have attended higher education, to smoke, to have fewer children, to use oral contraceptives, to have had a Pap smear in the past and to be HIV-positive. However, in a multivariate logistic regression model including the above variables and HPV status, only HPV positivity (P,0.001), increasing age (P,0.001), less education (0.01) and parity (0.04) were associated with cervical cancer.
Strong positivity for HPV was detected in 84.2 and 31.0 % of cervical samples from cases and controls, respectively (Table 2) . This increased to 90.5 and 41.4 %, respectively, when borderline HPV positivity was also classified as positive. Multiple infections were detected in 19.0 % of cancer biopsies and 8.9 % of cervical brush samples from controls (excluding borderline positivity). HPV 16, 18 and 45 were the most common types detected in cancer biopsies, being present in 49.8, 20.4 and 14.5 %, respectively (Table 2) . All other HPV types were present in ¡3.6 % of cancer biopsies (Table 2) . HPV 16, 18 and 'high-risk non-HPV 16 or 18' (HR non-HPV 16/18) types were associated with cervical cancer in both crude and adjusted analyses, with HPV 16 conveying the highest risk followed by HPV 18 and HR non-HPV 16/18 types (Table 3) . Low risk (LR) HPV types were negatively associated with cervical cancer in univariate but not in multivariate analyses.
To assess whether there was differential HPV type-specific cervical cancer risk according to HIV status, we performed separate analyses for HIV-positive and -negative women (Table 4 ). There was no evidence of effect modification on cervical cancer risk between HIV and HPV 16, 18, HR non-HPV 16/18 types or LR HPV types (Table 4 ). These analyses were adjusted for age since age was associated with both HIV status and cervical cancer. To assess the interaction between HIV and HPV type-specific cervical cancer risk further, we performed multivariate analyses that also included adjustment for infection with other HPV types, age, education and parity (these variables were associated with cervical cancer in the overall analysis). There was no evidence of effect modification on cancer risk between HIV and HPV 16, 18, HR non-HPV 16/18 or LR HPV types, but these analyses resulted in unstable estimates with large confidence intervals (data not shown). Separate analyses were also performed to assess the interaction between HIV and HPV type-specific cancer risk for each individual HPV type (except for HPV 16 and 18). There was no evidence of effect modification between HIV and HPV type-specific risk for any of the remaining HPV types analysed (P.0.20 for all HPV types investigated). In addition, a case-case analysis was performed where the HPV type distribution was compared between HIV-positive and -negative cancer cases. HPV 16 was detected in 40.8 % of cervical biopsies among HIV-positive women and 52.2 % among HIV-negative women (P50.16). HPV 18 was detected in 26.5 % of HIV-positive and 19.1 % of HIV-negative cancer cases (P50.26). There was no significant difference in the prevalence of any other HPV types in cervical cancers when HIV-positive and HPVnegative women were compared (P.0.14 for all HPV types investigated).
DISCUSSION
We performed a hospital-based case-control study to assess HPV type-specific cervical cancer risk according to HIV status in a population in which HIV is endemic. We report that HPV 16 and 18 were the HPV types most commonly associated with cervical cancer, both among HIV-positive and HIV-negative women.
HPV infection is more common and more likely to persist among HIV-positive than HIV-negative women (Ahdieh et al., 2001; Moscicki et al., 2004; Sun et al., 1997) . A previous study by Strickler et al. (2003) reported that the effect of immune status, measured as CD4 + cell count among HIV-positive women, was relatively less important for HPV 16 prevalence compared with other HPV types. Since there are several oncogenic HPV types, this could result in the relative attribution of HPV 16 to cervical cancer decreasing and that of other HPV types increasing among immunocompromised women. We did not observe a significantly different HPV-type distribution in cancer biopsies between HIV-positive compared with HIV-negative women in Mozambique. However, the prevalence of HPV 16 was 40.8 % in cancer biopsies from HIV-positive women compared with 52.2 % from HIV-negative women, and it might be that we could not detect a difference because of the limited sample size of our study. A recently published crosssectional study of cervical cancers from Kenya reported that there was no difference in HPV 16 prevalence in HIVpositive compared to HIV-negative women (De Vuyst et al., 2008) . In comparison, a meta-analysis of HIV type-specific prevalence among women with high-grade intraepithelial lesions (HSIL), a precursor for cervical cancer, reported that HPV 16 was less common among HIV-positive women (Clifford et al., 2006) . Though this analysis was based on a considerable sample size, HSIL is a less stringent end point than cervical cancer. It will be important to perform a similar analysis with cervical cancer as the end point. Furthermore, it will be important to assess type-specific cervical cancer risk among HIV-positive women in different geographical regions, since a lack of micronutrient intake and chronic infections, such as helminthic infections in Africa, might cause immunosuppression and hence dilute an association between specific HPV infections and HIV status (Strickler et al., 2008) .
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DSamples with a fluorescence intensity of up to twice the cut-off were regarded as being borderline-positive (see Methods explanation is the usage of different HPV-detection systems. In the other study SPF10-LiPA25, a very sensitive PCR method, was used (Kleter et al., 1999) . Higher test sensitivity as a possible explanation is supported by the higher prevalence of multiple infections in cancer biopsies (36 %) compared with our study (19 %). If we also include borderline-positive HPV results, the prevalences of HPV 51 and 52 in cervical cancers were 5.9 and 5.0 %, respectively. Another issue that must always be considered is the possibility of contamination. It is well known that paraffinembedded biopsies are sensitive to contamination, as the possibilities for pathology laboratories to maintain sterile conditions may be limited.
Confounding of type-specific cervical cancer risk owing to detection of multiple infections is a problem in all cervical cancer studies (Schiffman et al., 2009) . We assessed this by adjusting for other HPV infections in the multivariate models (Naucler et al., 2007) . However, owing to sparsesample bias it was not possible to adjust for each individual HPV type, and less common HPV types were grouped into the HR non-HPV 16/18 and LR HPV types (Rothman & Greenland, 1998) . Hence, we cannot exclude residual confounding caused by concomitant HPV infections.
There are several limitations to our study. First, hospitalbased studies are likely to include some selection bias in the choice of controls. This bias might be the reason for our surprising finding that HIV infection was more common among controls than among women with cervical cancer in our study. We did not obtain residential data from the study subjects and it is possible that cancer cases came from a larger geographical area, i.e. including the area also outside Maputo (the Central Hospital in Maputo is a referral hospital for the south of Mozambique), whereas controls, women with often benign pathologies seeking health care at the outpatient clinic of the Department of Otolaryngology, were principally from Maputo where the HIV prevalence has been reported to be higher than in other parts of the country (UNAIDS, 2011). Otolaryngological manifestations of HIV are common, such as ear, nose and throat infections and primary neurological damage, which could also explain the high HIV prevalence among controls. If HIV status results in a lower relative prevalence of HPV 16, as has been suggested previously, and there was oversampling of HIV-positive women among controls, our overall analysis including all subjects would result in an overestimate of the relative risk of HPV 16. However, our analyses according to HIV status are unlikely to have been influenced since the prevalence of HPV 16 among HIVpositive and -negative controls, respectively, would not have been affected. The negative association between HIV and cervical cancer was neither explained by age nor education (a surrogate marker for socio-economic status) as HIV was more common among controls compared with cancer cases in all age groups as well as educational categories (data not shown). Neither was it explained by increased Pap smear screening among HIV-positive patients, as 18.1 % of HIV-positive compared with 15.7 % of HIV-negative patients reported having had a Pap smear in the past (P50.55). As the negative association between HIV and cervical cancer was not significant after adjustment for other potential confounders (P50.14), chance is another likely explanation.
Second, the study considered age by adjustment rather than by matching, and control women were younger than the cancer cases. The reason for matching is not to remove , 33, 35, 39, 45, 51, 52, 56, 58 and 59. §LR HPV includes HPV types 6, 11, 42, 43, 66, 68, 70, 73 and 82. ||Not adjusted for other HPV types.
confounding, but to improve statistical efficiency. However, the benefits of matching are often overvalued and multivariate analysis is often preferable (Rothman & Greenland, 1998) . Furthermore, the logistics of performing a case-control study in Mozambique made age-matching practically impossible. We adjusted for age by 5-year age categories because of the limited study size, and residual confounding owing to smaller age differences therefore cannot be ruled out. Considerable confounding owing to age is unlikely to have occurred since there was no notable difference in HPV 16 or 18 distributions according to age category among cases or controls (all values of P.0.23).
Third, despite the fact that there was no evidence of effect modification between HIV and any of the HPV types investigated, our study did not have the statistical power to assess HPV type-specific cervical cancer risk according to HIV status for the less common HPV types. Lack of statistical power might yield type 2 errors, i.e. false-negative results, and hence future studies that assess the interaction between immunosuppression and HPV type-specific cancer risk will need to be of considerable size, since the study of interactions requires a larger study size compared with studies investigating the primary effect of a risk factor.
Fourth, we did not obtain detailed information on immune status (CD4 + cell count), HIV treatment, time of acquisition of HIV and HPV infections, or whether study participants were aware of their HIV status at the time of enrolment. The sequence of events as well as level of immunosuppression could be important as HIV status might influence the persistence of HPV type-specific infection as well as cervical tumorigenesis (Strickler et al., 2008) . These questions need to be addressed in larger studies of HIV-positive women with detailed information on immune status, consecutive HPV type-specific data and development of cervical lesions.
Fifth, cervical samples for HPV testing were sampled differently for case patients (biopsy) than control patients (brush sample). However, previous studies have reported good concordance in paired HPV testing between biopsies and brush samples collected from the same patients, and hence we believe there is limited differential sample bias in our study (Quint et al., 2001) .
Our findings that HPV type-specific cervical cancer risk is not influenced greatly by HIV infection should be followed-up with larger studies from different geographical regions. However, our results are encouraging since they suggest that HPV vaccines targeting HPV 16 and 18 might not need to be type-specifically modified for populations where HIV is endemic.
METHODS
Population. Consecutive enrolment of women with suspected invasive cervical cancer at the Department of Obstetrics and Gynaecology, Central Hospital in Maputo, Mozambique, was started In total, 335 women with suspected cervical cancer were enrolled. Out of these women 114 were excluded from analyses: nine had been enrolled twice and were now included only once, 18 had missing cervical samples, two did not have their cervical samples stored according to the protocol, 78 did not have invasive cervical cancer confirmed on histopathology review and seven did not have samples adequate for HPV testing (b-globin negative). Out of 207 controls that were enrolled, four women were excluded: two had been enrolled twice and were now included only once, one had a missing cervical sample and one did not have a sample adequate for HPV testing (bglobin negative). Of the control women, 9 % had an abnormal smear and none had cytological signs of invasive cancer. In total, 221 cases with confirmed invasive cervical cancer (217 squamous carcinomas and four adenocarcinomas) and 203 controls were included in the final analyses.
HPV DNA testing. Cervical biopsies and brush samples were stored in 3 M guanidinium thiocyanate, a general protein denaturant. Samples were stored at 220 uC in the Central Hospital in Maputo before shipment to Sweden. In Sweden, HPV DNA testing was performed by PCR with a modification of the general primer system GP5+/6+ (Söderlund-Strand et al., 2009) . The modified general primers are based on five forward and five reverse primers, each of which have a few modified nucleotides, compared with GP5+/6+, for better annealing. This has resulted in improved sensitivity for a number of HPV types, as compared with the GP5+/6+ primers (Söderlund-Strand et al., 2009 ). HPV typing was performed with a Luminex system with type-specific probes for 22 individual HPV types (HPV 6, 11, 16, 18, 31, 33, 35, 35:6624A (an HPV35 variant), 39, 42, 43, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 82) and one general HPV probe attached to fluorescent beads. Samples that were positive only for the general probe were typed by DNA sequencing (Schmitt et al., 2006; Söderlund-Strand et al., 2009) . Individual cut-off levels for each probe were established by using the median fluorescence intensity (MFI) of the negative controls (water) plus 56SD of these MFIs, with the proviso that a cut-off must not be less than 5 MFI units (Söderlund-Strand et al., 2009) . Samples with a fluorescence intensity of up to twice the cut-off value were regarded as being weakly positive (borderline-positive). Samples with a fluorescence intensity greater than twice the cut-off level were regarded as being strongly positive. A b-globin test was used to check for sample quality (Söderlund-Strand et al., 2009 ).
HIV serology. HIV testing was performed by a certified clinical microbiology laboratory in Sweden according to the routine HIV testing systems used. For the first 133 cases and 80 controls, HIV testing was performed with an Axsym system (Abbot). As the certified method was changed to ARCHITECT HIV Ag/Ab Combo (Abbott), this was used for the last 88 cases and 123 controls. Confirmation of samples that were HIV-positive during screening was performed with RIBA HIV-1/HIV-2 SIA (Chiron) throughout. Results were given to the doctor in Mozambique for further clinical management.
Statistical methods. Univariate and multivariate logistic regression models with 95 % confidence intervals were used to assess HPV typespecific cervical cancer risk. Type-specific risk was assessed for HPV 16 and 18 separately since these types are the most important attributable risk factors for cervical cancer in epidemiological studies worldwide (Cogliano et al., 2005; Schiffman et al., 2009) . To avoid sparse-sample bias, other HPV types that are attributed to a lesser proportion of cervical cancers worldwide (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) were grouped as HR non-HPV 16/18 (Cogliano et al., 2005; Schiffman et al., 2009) . HPV types previously defined as probably being non-carcinogenic (HPV 6, 11, 42, 43, 66, 68, 70, 73 and 82) were grouped as low-risk types (LR HPV) (Cogliano et al., 2005; Schiffman et al., 2009) . Women testing negative for the specific HPV type(s) under investigation were used as the reference category. Socio-demographic factors previously described to be associated with cervical cancer, as well as factors associated with cervical cancer at an a level of 0.2, were included in the multivariate models. Age at first pregnancy was not included in the multivariate model as information was missing for 44 women (Table 1) . Age was divided into 5-year age bands (¡30, 31-35, 36-40, 41-45, 46-50 and ¢51) . A likelihood test was performed to assess whether the association with cervical cancer departed from linearity for socio-demographic variables with more than two categories. If the variable did not depart from linearity it was introduced as a linear term in the multivariate model. In cases where multiple HPV types are detected in cervical cancer samples it is difficult to ascertain which HPV type is attributable to the cancer.
To reduce the risk of confounding of concomitant HPV infections, adjustment for other HPV types was performed by including HPV 16, HPV 18, HR non-HPV 16/18 and LR HPV as single variables in a multivariate model (Naucler et al., 2007) . Analyses of the overall HPV type-specific cervical cancer risk were performed by both excluding and including borderline positivity in the HPV test. The inclusion of borderline-positive HPV types as positives resulted in minor differences in the OR but an increase in the number of cervical cancer biopsies with more than four HPV types detected (three cervical cancer samples had 9, 11 and 13 HPV types detected, respectively). We cannot exclude that these findings may have been caused by contamination, and hence in performing all of the presented analyses borderline positivity was classified as being negative. HPV typespecific cervical cancer risk was analysed for HIV-positive and HIVnegative women separately. To assess whether HIV modifies the risk of HPV type-specific cervical cancer risk, an interaction term was introduced in the logistic regression model in the case-control analyses and a significance test was performed by using a likelihood ratio test. Furthermore, we performed a case-case comparison of HPV type distribution between HIV-positive and HIV-negative cancer cases.
